La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Roche Holding a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Roche Holding..

Roche Holding (OTC:RHHBY) Azioni, Catena delle Opzioni

Roche Holding

ROCHE HLDG LTD SPONS

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Weight Loss Drugs

Biotech

News

Health Care

General

CHGCY

RHHBY

Un farmaco nato per un altro scopo potrebbe risolvere il più grande effetto collaterale delle nuove terapie dimagranti.

Perdere peso senza perdere muscoli: la scommessa di Eli Lilly

ROCHE HOLDING LTD S/ADR by Roche Holding Ltd

Roche Holding AG

Press Releases

Stopping Cancer Before It Spreads: The EMT Revolution in Oncology

Small Cap

Roche receives CE Mark for Accu-Chek SmartGuide Continuous Glucose Monitoring and mySugr App integration, offering an enhanced diabetes management experience

Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH

Roche achieves first CLIA 'Moderate Complexity' categorization for Ionify® 25-Hydroxy Vitamin D total test

CHMP recommends EU approval of Roche's subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma

89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB

Positive phase III results show Roche's giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer

Positive Phase III Results Show Genentech's Giredestrant Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer

Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025

Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025

ETNB

PPCB

TD Cowen

Cowen & Co.

Comments

Roche Holding

Roche Holding (RHHBY) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO